Transaction DateRecipientSharesTypePriceValue
29th December 2020Troy A. Ignelzi2,131Exercise of derivative$9.20$19,605.20
29th December 2020Troy A. Ignelzi5,869Exercise of derivative$9.20$53,994.80
18th December 2020Steven M Paul15,000Open or private sale$140.00$2,100,000.00
18th December 2020Steven M Paul15,000Exercise of derivative$9.30$139,500.00
14th December 2020Atul Pande5,714Open or private sale$92.64$529,344.96
14th December 2020Andrew Craig Miller12,500Exercise of derivative$2.92$36,500.00
14th December 2020Atul Pande5,714Exercise of derivative$2.92$16,684.88
10th December 2020Andrew Craig Miller3,571Open or private sale$94.82$338,602.22
10th December 2020Andrew Craig Miller1,429Open or private sale$94.82$135,497.78
10th December 2020Andrew Craig Miller1,429Exercise of derivative$9.20$13,146.80
Karuna Therapeutics
Karuna Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 7/10.

Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company develops treatments for people afflicted with schizophrenia.

Ticker: KRTX
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1771917
Employees: 19
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags